Home
RCKT
RCKT News

Latest Rocket Pharmaceuticals Inc. (RCKT) News on October 28, 2025

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Zacks

13 days ago

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

MT Newswires

14 days ago

Rocket Pharma Gets FDA Review Date for Severe Immune Disorder Drug Candidate

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Business Wire

14 days ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

18 days ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Zacks

2 months ago

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket to relaunch rare disease trial after FDA approval

Clinical Trials Arena

2 months ago

Rocket to relaunch rare disease trial after FDA approval

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Barrons.com

2 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Associated Press Finance

2 months ago

BC-Most Active Stocks

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

MT Newswires

2 months ago

Traders Digest Retail Earnings Ahead of Fed Minutes, Driving Muted Premarket Action for US Equity Futures

MT Newswires

2 months ago

Rocket Pharmaceuticals Says US FDA Lifts Clinical Hold of Mid-Stage RP-A501 Study; Shares Up Pre-Bell

MT Newswires

2 months ago

Top Premarket Gainers

MT Newswires

3 months ago

Rocket Pharmaceuticals' Drug Candidate for Heart Condition Receives FDA RMAT Designation

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Business Wire

3 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701

Insider Monkey

3 months ago

Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701

MT Newswires

3 months ago

Rocket Pharmaceuticals Names Christopher Stevens as Chief Operating Officer

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.

Barrons.com

4 months ago

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.

Barrons.com

4 months ago

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.

MT Newswires

4 months ago

UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating

MT Newswires

5 months ago

Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target

MT Newswires

5 months ago

JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44

Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow

Insider Monkey

5 months ago

Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Benzinga

5 months ago

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback

Insider Monkey

5 months ago

William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback

RCKT Stock Tanks on Patient Death in Danon Disease Study

Zacks

5 months ago

RCKT Stock Tanks on Patient Death in Danon Disease Study

MT Newswires

5 months ago

Chardan Cuts Price Target on Rocket Pharmaceuticals to $17 From $46, Keeps Buy Rating

MT Newswires

5 months ago

Jefferies Downgrades Rocket Pharmaceuticals to Hold From Buy, Adjusts Price Target to $2.50 From $29

MT Newswires

5 months ago

Needham Downgrades Rocket Pharmaceuticals to Hold From Buy

MT Newswires

5 months ago

Morgan Stanley Downgrades Rocket Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $7 From $42

MT Newswires

5 months ago

Leerink Downgrades Rocket Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $8 From $37

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

Insider Monkey

5 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

Patient dies in Rocket’s Phase II Danon disease gene therapy trial

Clinical Trials Arena

5 months ago

Patient dies in Rocket’s Phase II Danon disease gene therapy trial

Gene Therapy Death Worsens Picture for an Already Troubled Field

Barrons.com

5 months ago

Gene Therapy Death Worsens Picture for an Already Troubled Field

MT Newswires

5 months ago

TD Cowen Downgrades Rocket Pharmaceuticals to Hold From Buy

MT Newswires

5 months ago

Sector Update: Health Care Stocks Rise Premarket Tuesday

MT Newswires

5 months ago

Rocket Pharmaceuticals Says US FDA Places Clinical Hold on Danon Disease Trial After Patient Death

MT Newswires

5 months ago

Top Premarket Decliners

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Business Wire

5 months ago

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

MT Newswires

5 months ago

Chardan Ups Price Target on Rocket Pharmaceuticals to $46 From $45, Maintains Buy Rating

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Business Wire

5 months ago

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?

Insider Monkey

6 months ago

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?

MT Newswires

6 months ago

Chardan Adjusts Price Target on Rocket Pharmaceuticals to $45 From $54, Maintains Buy Rating

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Business Wire

6 months ago

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks

6 months ago

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Associated Press Finance

6 months ago

Rocket Pharmaceuticals: Q1 Earnings Snapshot

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Business Wire

6 months ago

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 04/25/2025

High Growth Tech Stocks To Watch In The US April 2025

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In The US April 2025

Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz

TipRanks

6 months ago

Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz

Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

6 months ago

Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans?

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 04/15/2025

Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple

Insider Monkey

7 months ago

Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Business Wire

7 months ago

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

7 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now?

Insider Monkey

7 months ago

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now?

MT Newswires

8 months ago

BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target

Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory

Insider Monkey

8 months ago

Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory

When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit?

Simply Wall St.

8 months ago

When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit?

Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus

Zacks

8 months ago

Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus

Associated Press Finance

8 months ago

Rocket Pharmaceuticals: Q4 Earnings Snapshot

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Business Wire

8 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

9 months ago

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

10 months ago

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’

TipRanks

10 months ago

Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’

MT Newswires

10 months ago

Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says

MT Newswires

10 months ago

Wedbush Initiates Rocket Pharmaceuticals at Outperform With $32 Price Target

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

10 months ago

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Investopedia

10 months ago

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

MT Newswires

10 months ago

Jefferies Initiates Coverage on Rocket Pharmaceuticals With Buy Rating, $29 Price Target

MT Newswires

a year ago

Rocket Pharmaceuticals Prices Upsized $165 Million Stock Offering

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Business Wire

a year ago

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

MT Newswires

a year ago

Rocket Pharmaceuticals Plans $150 Million Public Offering of Common Shares

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire

a year ago

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Business Wire

a year ago

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Benzinga

a year ago

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

MT Newswires

a year ago

Sector Update: Health Care Stocks Lean Lower Premarket Tuesday

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Rocket Pharmaceuticals to Resume Patient Enrollment in RP-L301 Gene Therapy Phase 2 Trial in 2025

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Business Wire

a year ago

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions

Business Wire

a year ago

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Zacks

a year ago

Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Business Wire

a year ago

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Associated Press Finance

a year ago

Rocket Pharmaceuticals: Q3 Earnings Snapshot

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Business Wire

a year ago

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation

MT Newswires

a year ago

Scotiabank Initiates Rocket Pharmaceuticals at Sector Outperform With $50 Price Target

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Business Wire

a year ago

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Business Wire

a year ago

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

Zacks

a year ago

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?

Zacks

a year ago

Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

MT Newswires

a year ago

Rocket Pharmaceuticals Files Mixed-Shelf Offering

Associated Press Finance

a year ago

Rocket Pharmaceuticals: Q2 Earnings Snapshot

Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?

Insider Monkey

a year ago

Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?

MT Newswires

a year ago

Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $40 From $49, Maintains Buy Rating

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Zacks

a year ago

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

MT Newswires

a year ago

Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating

MT Newswires

a year ago

Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides

Benzinga

a year ago

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides

Share on Social Networks: